Bonaventura Clotet

Bonaventura Clotet

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in The Lancet
Verified
Journal Article
Closed access
BCBonaventura Clotet
Bonaventura Clotet
JFJudith Feinberg
Judith Feinberg
JLJan van Lunzen
Jan van Lunzen
MKMarie-Aude Khuong-Josses
Marie-Aude Khuong-Josses
AAAndrea Antinori
Andrea Antinori
SMSherene Min
Sherene Min

1 April 2007 in The Lancet
Verified
Journal Article
Closed access
BCBonaventura Clotet
Bonaventura Clotet
NBNicholas Bellos
Nicholas Bellos
JMJean-Michel Molina
Jean-Michel Molina
DCDavid Cooper
David Cooper
JGJean-Christophe Goffard
Jean-Christophe Goffard
ELEric Lefebvre
Eric Lefebvre

7 December 2011 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
BMBeatriz Mothe
Beatriz Mothe
ALAnuska Llano
Anuska Llano
JIJavier Ibarrondo
Javier Ibarrondo
MDMarcus Daniels
Marcus Daniels
CMCristina Miranda
Cristina Miranda
CBChristian Brander
Christian Brander
Background: The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell function and specificity. Methods: Here, 950 untreated HIV-1 clade B or -C infected individuals were tested for responses to sets of 410 overlapping peptides (OLP) spanning the entire HIV-1 proteome. For each OLP, a "protective ratio" (PR) was calculated as the ratio of median viral loads (VL) between OLP non-responders and responders. Results: For both clades, there was a negative relationship between the PR and the entropy of the OLP sequence. There was also a significant additive effect of multiple responses to beneficial OLP. Responses to beneficial OLP were of significantly higher functional avidity than responses to non-beneficial OLP. They also had superior in-vitro antiviral activities and, importantly, were at least as predictive of individuals' viral loads than their HLA class I genotypes. Conclusions: The data thus identify immunogen sequence candidates for HIV and provide an approach for T cell immunogen design applicable to other viral infections.

14 January 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
AAAna Abecasis
Ana Abecasis
AWannemarie M.J. wensing
annemarie M.J. wensing
Dimitrios ParaskevisDimitrios Paraskevis
Dimitrios Paraskevis
JVJurgen Vercauteren
Jurgen Vercauteren
KTKristof Theys
Kristof Theys
AVAnne-Mieke Vandamme
Anne-Mieke Vandamme
Understanding HIV-1 subtype distribution and epidemiology can assist preventive measures and clinical decisions. Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes.

1 March 2021 in Med
Verified
Journal Article
Closed access
EPEdwards Pradenas
Edwards Pradenas
BTBenjamin Trinité
Benjamin Trinité
VUVíctor Urrea
Víctor Urrea
SMSilvia Marfil
Silvia Marfil
CÁCarlos Ávila-Nieto
Carlos Ávila-Nieto
JBJulià Blanco
Julià Blanco

25 July 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
GMGloria Martrus
Gloria Martrus
MNMaria Nevot
Maria Nevot
CACristina Andrés
Cristina Andrés
BCBonaventura Clotet
Bonaventura Clotet
Miguel Angel MartinezMiguel Angel Martinez
Miguel Angel Martinez
Background: Human immunodeficiency virus type 1 (HIV-1) has a biased nucleotide composition different from human genes. This raises the question of how evolution has chosen the nucleotide sequence of HIV-1 that is observed today, or to what extent the actual encoding contributes to virus replication capacity, evolvability and pathogenesis. Here, we applied the previously described synthetic attenuated virus engineering (SAVE) approach to HIV-1. Results: Using synonymous codon pairs, we rationally recoded and codon pair–optimized and deoptimized different moieties of the HIV-1 gag and pol genes. Deoptimized viruses had significantly lower viral replication capacity in MT-4 and peripheral blood mononuclear cells (PBMCs). Varying degrees of ex vivo attenuation were obtained, depending upon both the specific deoptimized region and the number of deoptimized codons. A protease optimized virus carrying 38 synonymous mutations was not attenuated and displayed a replication capacity similar to that of the wild-type virus in MT-4 cells and PBMCs. Although attenuation is based on several tens of nucleotide changes, deoptimized HIV-1 reverted to wild-type virulence after serial passages in MT-4 cells. Remarkably, no reversion was observed in the optimized virus. Conclusion: These data demonstrate that SAVE is a useful strategy to phenotypically affect the replicative properties of HIV-1.